



OPEN

Antibacterial composite coatings of MgB₂ powders embedded in PVP matrix

P. Badica^{1✉}, N. D. Batalu², M. Burdusel¹, M. A. Grigorescu¹, G. Aldica¹, M. Enculescu¹, G. Gradisteanu Pircalabioru³, M. Popa³, L. G. Marutescu³, B. G. Dumitriu⁴, L. Olariu^{4,6}, A. Bicu⁴, B. Purcareanu⁴, L. Operti⁵, V. Bonino⁵, A. Agostino⁵, M. Truccato⁵ & M. C. Chifriuc³

Three commercial powders of MgB₂ were tested in vitro by MTS and LDH cytotoxicity tests on the HS27 dermal cell line. Depending on powders, the toxicity concentrations were established in the range of 8.3–33.2 µg/ml. The powder with the lowest toxicity limit was embedded into polyvinylpyrrolidone (PVP), a biocompatible and biodegradable polymer, for two different concentrations. The self-replenishing MgB₂-PVP composite materials were coated on substrate materials (plastic foil of the reservoir and silicon tubes) composing a commercial urinary catheter. The influence of the PVP-reference and MgB₂-PVP novel coatings on the bacterial growth of *Staphylococcus aureus* ATCC 25923, *Enterococcus faecium* DMS 13590, *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, in planktonic and biofilm state was assessed in vitro at 6, 24, and 48 h of incubation time. The MgB₂-PVP coatings are efficient both against planktonic microbes and microbial biofilms. Results open promising applications for the use of MgB₂ in the design of anti-infective strategies for different biomedical devices and systems.

The opportunistic and nosocomial agents, such as ESCAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Clostridium difficile*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and Enterobacteriaceae) pathogens and *Candida albicans* represent one of the most important global threats for the public health. They have the ability to adhere and develop biofilms on live tissues and implanted medical devices, consequently producing biofilm associated infections¹. Biofilms exhibit a particular form of resistance, the phenotypic resistance or tolerance. They also have recalcitrance, i.e. the ability to survive in the presence of high concentrations of antibiotics².

The multiple negative consequences of biofilms development in the clinical sector underlines the need to recognize the problems contributing to poor outcomes and high costs. It also highlights the necessity of a multidisciplinary effort to prevent, combat, or eradicate biofilms. The antimicrobial strategies can be divided in microbiostatic/microbicidal based agents or on antipathogenic agents. The first ones involve the use of agents which inhibit or kill microorganisms, while the antipathogenic ones target the expression of virulence factors (e.g., adherence capacity, toxigenicity) and of their regulators (Quorum Sensing inhibitors)³. The antibiofilm strategies belong to both categories of the antimicrobial ones.

Nanotechnology and nanomaterials are of much interest for the development of new antimicrobial approaches, based on either novel biomaterials or on improving the biological properties of the existing ones. Currently, in a sustainable and eco-friendly driven approach, many studies are directed to design both clinically and environmentally safe nanomaterials (NMs) for antimicrobial applications. The NMs act as antimicrobial and antibiofilm agents. They can have additive or synergetic effects in combinations with antibiotics or other antimicrobials^{4–7}. NMs are also useful as drug delivery for targeted release to the site of infection and as components of composites including stimuli-responsive coatings, or modified hybrid materials^{8–10}. Many physico-chemical properties, such as the type of the nanomaterial, size, morphology, specific surface-area-to-volume ratio, surface charge, concentration, behavior in biological medium and pH, stability and others are conditioning their antibiofilm effect. All these factors influence the contact with the biofilm matrix and biofilm embedded cells, affecting the release of reactive oxygen species, of antimicrobial ions or of the loaded bioactive compounds¹¹. NMs can be

¹National Institute of Materials Physics, Street Atomistilor 405A, 077125 Magurele, Romania. ²University Politehnica of Bucharest, Splaiul Independentei 313, 060042 Bucharest, Romania. ³Faculty of Biology and The Research Institute of the University of Bucharest (ICUB), University of Bucharest, Splaiul Independentei 91-95, Bucharest, Romania. ⁴Biotehnos SA, Strada Gorunului, Nr. 3-5, Otopeni, Județul Ilfov, Romania. ⁵Physics and Chemistry Departments, University of Turin, Via P. Giuria 1-7, 10125 Turin, Italy. ⁶Academy of Romanian Scientists, 54 Splaiul Independentei, 050094 Bucharest, Romania. ✉email: badica2003@yahoo.com

modified through functionalization to increase their efficacy and biocompatibility¹². They can simultaneously attack multiple microbial targets, thereby the risk of emergence of resistance is low. The NMs can interfere with different stages of biofilm development, i.e., with single-cell adherence, multiplication, and colonization of the substrate, with biofilm maturation, and with biofilm dispersion. They can interact with the planktonic cells, inhibiting either the initial adhesion to a substrate and the dispersion, or with the biofilm matrix by facilitating the biofilm penetration, drug release, or further interaction with the biofilm cells¹³.

Metals (silver, copper, gold, chromium), metal oxides (Al_2O_3 , CeO_2 , Co_3O_4 , Cr_2O_3 , CuO , In_2O_3 , Fe_2O_3 , MgO , Mn_2O_3 , NiO , Ni_2O_3 , SiO_2 , TiO_2 , ZnO , ZrO_2 , Y_2O_3 , etc.), metal hydroxides, such as $\text{Mg}(\text{OH})_2$, and metal halides nanoparticles (NPs) are among the most studied NMs for antimicrobial effects, due to their intrinsic antimicrobial features^{11,14–18}. They exhibit both microbicidal and microbiostatic effects caused by membrane lesions due to the direct contact with NPs and the release of free metal ions, the proteins inactivation, the nucleic acids damage, the release of reactive oxygen species (ROS), and stimulation of the host immune system.

The delivery of active NPs inside biofilms is possible by using different delivery systems, including polymers. Polyvinylpyrrolidone (PVP), also called polyvidone or povidone, is a biocompatible, non-toxic, biodegradable, hydrophilic polymer with good binding properties and with a stabilizing effect on suspensions and emulsions. PVP is recognized as safe by the Food and Drug Administration (FDA). Considering also that it has other unique physical and chemical features, e.g. it is chemically inert, but soluble in water and alcohol, can have different morphologies, it is colorless, temperature-resistant and pH-stable, PVP is largely used for biomedical applications^{19–21}.

In this paper, we continue our previous studies on antimicrobial activity of MgB_2 powders^{22,23} and we investigate their potential when embedded in PVP-based polymeric coatings for fabrication of improved plastic medical devices, more resistant to microbial colonization and thus, less probable to induce biofilm-associated infections. As substrate materials we use a flexible plastic foil of a urinary catheter reservoir and silicon tubes from the same commercial device. The challenges in using catheter devices and criteria for their improvement are reviewed in Refs.^{24,25}. The MgB_2 compound is degradable in water^{26,27} and it results that the composite coatings of PVP- MgB_2 are biodegradable and self-replenishing. Other different factors that recommend MgB_2 for biomedical application are: (i) as already mentioned, Mg is an antimicrobial material, but also boron in the form of boric acid or sodium salts of boron (borax, disodium tetraborate) is an effective antiseptic, bactericidal, insecticidal, herbicidal and cleaning agent used in detergents²⁸ and therein Refs.); (ii) on the other hand, both Mg and boron are involved in the metabolism of humans from bone growth to wound healing and their amount in the body is relatively high; boron has positive effects and it is used in treatment of cancer and infections; (iii) MgB_2 is a light weight compound with bulk density of 2.63 g/cm^3 that is close to that of the bones; (iv) the mechanical properties of MgB_2 are similar to those of ceramic materials and of the bones; (v) MgB_2 has metallic conduction and when decomposes it releases positive (Mg) and negative (B) ions impacting local pH and interaction with negatively charged cellular wall; (v) there is a family of MgB_γ (MgB_4 , MgB_7 , MgB_{12} , MgB_{19}) phases that may prove of interest to control the bioprocesses depending on application requirements.

Experimental

Physico-chemical characteristics of MgB_2 raw powders. Commercial raw powders of MgB_2 were produced by LTS Research Laboratories Inc (LTS), Alfa Aesar (AA), and CERAC Inc (CER). The powders have very different physico-chemical properties. Although results will be presented elsewhere²³, according to X-ray diffraction measurements and Rietveld analysis, we mention that powders were composed of the main phase MgB_2 and of the secondary phases MgO and MgB_4 . The highest MgB_2 amount was measured in LTS (97 wt. % MgB_2) followed by Alfa Aesar (88 wt. % MgB_2), and Cerac (80.3 wt. % MgB_2). In the same order, the amount of residual unreacted metallic Mg (1.2–0 wt. %) decreases, while the amount of secondary phases MgO (1.8–7.9 wt. %) and MgB_4 (0–11.8 wt. %) increases. The crystallite size of the powders is comparable (105–113 nm). In the LTS and Alfa Aesar powders, the amount of carbon (denoted γ) substituting for boron in the crystal lattice of MgB_2 is not much different ($\gamma=0.0011/0.0015$). In the Cerac powder γ is more than double (0.0039), considering the chemical formula $\text{Mg}(\text{B}_{1-\gamma}\text{C}_\gamma)_2$. The powders have a bimodal particle size distribution. The LTS powders, followed by Alfa Aesar and Cerac, show high and low intensities of the peaks for the small and large size fractions, respectively. The large size fraction is composed of stable particle agglomerates. A higher fraction of small particles explains the lower flowability and a higher rate of pH increase (for powders immersed in water) towards saturation of LTS followed by Alfa Aesar and Cerac. The pH saturation is within a narrow range of 9.9 and 10.1. The surface of the particles was studied by TEM and it was appreciated that surfaces are relatively clean, lacking oxides and impurities.

MgB_2 raw powders cytocompatibility tests. The cytotoxic (loss of viable cells) effect of MgB_2 powders on fibroblast HS-27 (skin) cell line is assessed by observing the correlated change in cell viability (MTS test²⁹) and enzymatic activity in the culture medium (LDH test). Since the main function of fibroblasts is to maintain the structural integrity of connective tissue by synthesizing extracellular matrix components (particularly, type I collagen), the HS-27 line is a representative standard dermal cell line for testing primarily the potential of MgB_2 for topical use and related applications. In this work the quantitative results of this test are used as input guiding data for the design of the MgB_2 -PVP coatings compositions.

Cells were incubated with MTS (Kit: CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega) colorimetric assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)^{30,31}. The compound is reduced by living cells to purple and water-soluble formazan. The conversion of MTS to formazan takes place under the action of enzymes (dehydrogenases) from metabolically active cells. The absorbance of formazan at 490 nm is measured spectrophotometrically (TriStar Berthold Technologies) directly in the 96-well plates. The




Figure 1. Coatings fabrication stages: (a) coatings of PVP with different concentrations (0.5 g of PVP in 3–30 ml of ethanol) on a glass substrate; (b) coatings of MgB_2 -PVP with different concentrations (0.01–4 g of MgB_2 introduced into a solution of 0.5 g PVP/30 ml ethanol) on a glass substrate (see text); (c–e) coatings on the polymer foil of the catheter reservoir of PVP^{foil} (0.5 g PVP/30 ml ethanol), $(\text{MgB}_2\text{-PVP})^{\text{foil}}_{0.25}$ (0.25 g MgB_2 /0.5 g PVP/30 ml ethanol), $(\text{MgB}_2\text{-PVP})^{\text{foil}}_3$ (3 g MgB_2 /0.5 g PVP/30 ml ethanol), respectively; (f) (from left to right) pristine silicon tube of a catheter and coatings on the catheter silicon tube of PVP^{tube} (0.5 g PVP/30 ml ethanol), $(\text{MgB}_2\text{-PVP})^{\text{tube}}_{0.25}$ (0.25 g MgB_2 /0.5 g PVP/30 ml ethanol), $(\text{MgB}_2\text{-PVP})^{\text{tube}}_3$ (3 g MgB_2 /0.5 g PVP/30 ml ethanol).

amount of produced formazan is quantified by absorbance which is directly proportional to the number of living cells in the culture.

Lactate dehydrogenase (LDH) is a cytosolic enzyme from the cytoplasm of any cell. Damage to the cell membrane causes the leak of LDH into the extracellular fluid. In vitro release of LDH provides an accurate way to measure cell membrane integrity and, implicitly, cell viability³². To test the cytotoxic effect of MgB_2 on HS-27 cell culture, cells are exposed to increasing concentrations of MgB_2 solutions. The MgB_2 solutions used in the MTS and LDH experiments are the same and their preparation is addressed in the next paragraphs. The release of LDH in the cell culture supernatant correlates with the cytotoxicity^{33,34} and it is measured by a test in which two coupled enzymatic reactions, catalyzed by LDH and diaphorase, take place. The reactions convert a tetrazolium salt into a red formazan compound. Absorbance at 490 nm is measured spectrophotometrically (TriStar Berthold Technologies). The kit used in our experiments was CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega).

For each powder (LTS, Alpha Aesar and Cerac) two stock solutions (8.3 mg/ml and 33.3 mg/ml) in ethanol (99.8%) were prepared. Decimal dilutions were further used in the test. After 34 h adhesion time in 96-well culture plates, fibroblasts were treated with MgB_2 solutions for 48 h. The protocol involving an incubator for cell cultures with a humid atmosphere and 5% CO_2 at 37 °C) was applied, where the culture medium was composed of DMEM, 1% antibiotic/antifungal, 10% fetal bovine serum. The absorbance of the samples was related to that of the environmental control, the solvent control, and the cell control.

In the MTS and LDH tests, three experiments were performed using samples in triplicate. The absorbance ratio R of solutions with different concentrations containing treated and untreated cells in the MTS (R_{MTS}) and LDH (R_{LDH}) tests was plotted vs. concentration of MgB_2 solutions. For an increasing concentration, a decrease of R_{MTS} (equivalent to less formazan produced by fewer living cells) and an increase of R_{LDH} (equivalent to more LDH as a result of a lower metabolic activity due to more damaged cells) determine the cytotoxicity threshold.

Fabrication of composite MgB_2 -PVP coatings. The LTS powder with the highest antimicrobial activity²³ was selected for fabrication of MgB_2 -PVP composite coatings. Commercial polyvinylpyrrolidone (PVP) powder (Sigma Aldrich, the monomer N-vinylpyrrolidone, with chemical formula $\text{C}_6\text{H}_9\text{NO}$ and molar weight $M_w = 1,300,000$ g/mol) was dissolved in ethanol at room temperature. The amount of the PVP powder immersed in ethanol was constant, 0.5 g, and the volume of ethanol was modified from 3 to 30 ml. Droplets of each solution were placed on a glass substrate (Fig. 1a). A higher uniformity of the coating and less trapped gas particles were noticed for a lower concentration; hence the lowest tested concentration (0.5 g PVP/30 ml ethanol) was selected for further processing stages. The PVP polymer is also soluble in water and this property will be used to release the active MgB_2 particles when in contact with bacteria.

The MgB_2 powder was introduced into as-prepared PVP-ethanol solution and mixed ultrasonically for few minutes, and a colloidal black solution was obtained (Fig. 2I). MgB_2 is not soluble in alcohols³⁵. The amount of the MgB_2 powder varied from 0.01 to 4 g. Droplets of the colloidal solution were placed on a glass substrate and




Figure 2. Preparation of composite MgB_2 -PVP coatings (I–III), release of active MgB_2 from the composite coating and its decomposition in the presence of water/aqueous solution (IV), and the antimicrobial effect through possible mechanisms on different microbes. SEM image from III is taken on the sample $(\text{MgB}_2\text{-PVP})_{0.25}^{\text{foil}}$.

dried naturally under ambient conditions (Fig. 1b). The uniformity, bubbles size and amount, and adherence of the coatings were observed. Two concentrations, 0.25 and 3 g per initial solution (0.5 g PVP/30 ml ethanol) were selected. Considering the density of PVP of 1.2 g/cm^3 , the selected concentrations of MgB_2 in PVP are 60 mg/ml and 720 mg/ml, respectively. For MgB_2 concentrations in PVP greater than 720 mg/ml, coatings are not uniform, showing a high level of granularity that makes them easily breakable and removable from the substrate.

The plastic foil of a reservoir and the silicon tube, both from a commercial urinary catheter, were used as substrates for coatings fabrication (Fig. 1c–f). Coatings of bare PVP as reference samples were also deposited. The composite films on the plastic foils were obtained by dip coating and subsequent drying at room temperature (Fig. 2II,III). They were cut into samples of 8 mm in diameter (Fig. 1c–e). The PVP- MgB_2 composite covered both sides of the foil substrate. Colloidal solutions of MgB_2 /PVP/ethanol were poured into a silicon tube and, after drying, a coating was obtained inside the tube (Fig. 1f). The inner/outer diameter of the tube was 4.5/6 mm. After coating, the tube was cut into pieces of 1 cm in length.

Coated samples were labeled as: PVP^{foil} and PVP^{tube} (0.5 g PVP/30 ml ethanol), $(\text{MgB}_2\text{-PVP})_{0.25}^{\text{foil}}$ and $(\text{MgB}_2\text{-PVP})_{0.25}^{\text{tube}}$ (0.25 g MgB_2 /0.5 g PVP/30 ml ethanol), $(\text{MgB}_2\text{-PVP})_3^{\text{foil}}$ and $(\text{MgB}_2\text{-PVP})_3^{\text{tube}}$ (3 g MgB_2 /0.5 g PVP/30 ml ethanol).

The microstructure by scanning electron microscopy (SEM, Lyra 3XMU/Tescan) of the composite MgB_2 -PVP coatings (covered with Au) on the plastic foil can be visualized in Fig. 3. The surface morphology of the composite film changes with addition of a higher amount of MgB_2 powder in the coating. The presence of MgB_2 influences drying of the coating and its roughness. While drying improves and roughness decreases for sample $(\text{MgB}_2\text{-PVP})_{0.25}^{\text{foil}}$ (Fig. 3c,d) when compared to PVP^{foil} (Fig. 3a,b), addition of a higher amount of MgB_2 as for sample $(\text{MgB}_2\text{-PVP})_3^{\text{foil}}$ (Fig. 3e,f) produces a very rough and granular surface. In the sample $(\text{MgB}_2\text{-PVP})_3^{\text{foil}}$ one can actually clearly distinguish grains with plate like or irregular morphology (Fig. 3e,f) that are gathered into agglomerates. The morphology of the particles in the composite film is similar to that observed in the raw LTS MgB_2 powder²³. Elemental mapping shows the presence of B and Mg, distributed uniformly at the scale of our observation (Fig. 3g,h). This result and short-time sonication for low energy (200 W) suggests that the integrity of MgB_2 was preserved during its processing in the PVP-ethanol solution for preparation of the composite film. However, it is noteworthy that ultrasonication for 30 min at room temperature of MgB_2 in water produced through exfoliation Mg-deficient hydroxyl-functionalized nanosheets of MgB_2 ³⁶, while processing of MgB_2 in acetonitrile mixed with an ion-exchange resin leads to formation of borophane sheets (hydrogenated borophene, HB)³⁷.




Figure 3. SEM images at two magnifications ($\times 500$, $\times 1000$) on MgB_2 -PVP films coated on plastic foil: (a,b) sample PVP^{foil} ; (c,d) sample $(\text{MgB}_2\text{-PVP})^{\text{foil}}_{0.25}$; (e,f) sample $(\text{MgB}_2\text{-PVP})^{\text{foil}}_3$. Secondary electron image from (g) presents a detail at high magnification ($\times 15,000$) of sample $(\text{MgB}_2\text{-PVP})^{\text{foil}}_3$, while (h) is a red–green–blue image obtained by overlapping the elemental EDS maps of Mg and B measured on image from (g).

In vitro assay of antibacterial activity of MgB_2 -PVP coatings. The antimicrobial activity of the composite MgB_2 -PVP coatings (on foil and tubes) was tested against bacteria in planktonic and biofilms growth states (*Staphylococcus aureus* ATCC 25923, *Enterococcus faecium* DMS 13590, *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853).

In the case of planktonic bacteria, microbial suspensions of McFarland 0.5 (corresponding to 1.5×10^8 CFU/ml) were prepared from 24 h cultures in sterile saline solution. The obtained suspensions were further diluted




Figure 4. The absorbance ratio R in MTS and LDH cytotoxicity tests on HS27 cell line for dilutions prepared from stock solutions of 8.3 mg/ml of three types of MgB_2 powders.

1:100 in broth. Each composite MgB_2 -PVP sample was introduced into a well of a 24-well plate. The plate was inoculated with the prepared microbial suspension (750 μ l). The final inoculum size was of 5×10^5 CFU/ml for each tested coating. Untreated microbial cultures and sterile broth wells served as positive and negative controls. The inoculated 24 well-plates were incubated at 37 °C, in aerobic conditions for 6 h, 24 h, and 48 h. After incubation for the respective time intervals, the density of the microbial broth culture was determined by plating serial ten-fold dilutions prepared in sterile saline onto PCA (Plate Count Agar) and counting the number of colonies developed at different dilutions. Results were further used to determine the number of colonies forming units (CFU/ml).

In the case of biofilms, coatings were placed in contact with an inoculum of 5×10^5 CFU/ml obtained from each microbial strain and incubated for 6, 24, and 48 h. After incubation, each material was carefully washed to remove the non-adherent bacteria and sonicated in sterile saline solution to disperse the biofilm, and serial decimal dilutions were seeded on agar plates to determine the CFU/ml as presented above.

All assays were done in triplicate.

Results

Cytocompatibility of MgB_2 powders. All dilutions (66–333 μ g/ml) of stock solution with concentration 33.3 mg/ml and for the three investigated MgB_2 powders (LTS, Alfa Aesar and Cerac) have shown cytotoxicity on the H27 cell line. The effect of dilutions with smaller concentrations (0.83–83 μ g/ml) prepared from the stock solution 8.3 mg/ml are presented in Fig. 4. Concentrations of MgB_2 solutions below 8.3, 33.2, and 33.2 μ g/ml for the powders LTS, Alfa Aesar, and Cerac are compatible with the metabolism of fibroblasts without a toxic impact. In other experiments with different cells³⁸ the toxicity limit was in the range of 50–100 μ g/ml. The LTS powder has a lower biocompatibility than Alfa Aesar and Cerac powders.

Higher cytotoxicity of LTS comparative to the other MgB_2 investigated powders can be inferred from its low tendency to form large agglomerates, clean particle surfaces, high amount of MgB_2 phase, and high pH-increase rates²³. Different activity of different MgB_2 powders enables the possibility of a time and space-controlled reaction of MgB_2 with biological medium, depending on the application requirements, so that the toxic effect is minimized, and antibacterial impact is maximized.

For design purposes of the MgB_2 -PVP coatings, apart from the as-evaluated cytotoxicity concentrations, we considered the minimum inhibitory concentrations for the growth in the presence of LTS, Alfa Aesar and Cerac MgB_2 powders of different reference microbes (*Staphylococcus aureus* ATCC 25923, *Staphylococcus aureus* ATCC 6538, *Pseudomonas aeruginosa* ATCC 27853, *Escherichia coli* ATCC 25922, and *Candida albicans* ATCC 10231) in the planktonic (MIC) and biofilm (MICB) states reported in Ref.²³. Namely, the MIC and MBIC values ranged between 0.31 and 1.25 mg/ml and between 0.039 and 0.62 mg/ml, respectively. The highest antimicrobial activity was found for LTS and the lowest for Cerac. The MgB_2 powders were active also against planktonic cells and biofilms of 29 methicillin resistant clinical *S. aureus* isolates and 33 vancomycin resistant *E. faecium/faecalis* strains collected from clinical sources. The MIC values of 0.15–2.5 mg/ml were determined for different fungi collected from the heritage buildings and objects³⁸.

Antibacterial activity of MgB_2 -PVP composite coatings. The influence of PVP and MgB_2 -PVP coatings on the bacterial growth in planktonic state (in the liquid culture medium) and biofilm state (adhered on the surface of plastic foil or silicon catheter) was assessed at 6, 24, and 48 h of bacterial strains incubation with the tested samples. Results are presented in Figs. 5 and 6.

The general trend was that the MgB_2 -PVP samples exhibited an evident inhibitory activity on the planktonic growth of all tested strains, starting with 6 h of incubation, exacerbating after 24 h, and maintaining it at 48 h (Figs. 5, 6).

The inhibitory effect of the planktonic growth was more intense in the case of the samples (MgB_2 -PVP)^{foil}₃ containing the highest concentration of MgB_2 . In the case of the bacterial cells adhered on the surface of the functionalized plastic samples, the anti-biofilm effect was strain specific, but however, less evident than in the case of planktonic cells. The *E. coli* biofilm development was inhibited at all three time points by the (MgB_2 -PVP)^{foil}₃.




Figure 5. The number of viable microbial cells in \log_{10} (CFU/ml) for samples in the form of coatings on the plastic foil (i.e. samples PVP^{foil}, (MgB₂-PVP)^{foil}_{0.25}, (MgB₂-PVP)^{foil}₃) tested with microbes in planktonic and biofilm growth states.

The same sample inhibited the *P. aeruginosa* and *S. aureus* biofilm at 24 h and 48 h, respectively. In the case of *E. faecium*, all samples inhibited the initial cells adherence to the plastic foil, quantified after 6 h of incubation, and the (MgB₂-PVP)^{foil}₃ exhibited also a slight inhibitory effect against the 24 h biofilm (Fig. 5). The comparative behaviour of planktonic and adhered cells developed in the presence of MgB₂-functionalized plastic-foil samples suggests that the coatings exhibit their antimicrobial effect mostly by releasing the MgB₂ in the active form.

The rate of the bacterial strains growth in the presence of the MgB₂-functionalized silicon tubes was different from that recorded on the plastic samples, with no significant inhibition of the planktonic growth, except a slight decrease of the number of the viable cells of *S. aureus* after 24 h of incubation and of *E. coli* and *E. faecium* after 48 h of incubation. No significant differences between the PVP and MgB₂-PVP samples (Fig. 6) were noted. In the case of the bacterial cells adhered on the surface of the MgB₂-functionalized silicon tubes, the (MgB₂-PVP)^{tube}₃ inhibited the *P. aeruginosa* biofilm development, with the anti-biofilm effects intensity decreasing in time from 6 to 48 h. The (MgB₂-PVP)^{tube}_{0.25} sample has shown a slight tendency for inhibition of the *S. aureus* biofilm development, the effect being noticeable after 6 h of incubation. All samples slightly inhibited the development of *E. faecium* at all three incubation times. As for *S. aureus*, the effect is stronger at 6 h.

Results indicate that MgB₂-containing samples on foils are more active than the coatings on silicon tubes. To understand it, further research is necessary. Among the possible reasons there could be how the shape of the sample influences the contact with the cell growth, the release of MgB₂ and its interaction with the cells. A second aspect that could play a role is the fact that adherence of the coatings on the silicon tube is poor when compared to that on the foil. This is especially problematic for coatings with a high concentration of MgB₂, i.e. for the samples (MgB₂-PVP)^{tube}₃.

Discussion

Considering the data presented in “Cytocompatibility of MgB₂ powders” it results that selected MgB₂ powder for coatings fabrication, LTS, has the lowest toxicity limit, corresponding to the highest cytotoxicity. At the same time, this powder is the most active one from the viewpoint of antimicrobial efficiency, i.e. the MIC and MBIC values are the lowest²³. To understand the context of our antimicrobial assessment from “Antibacterial activity of




Figure 6. The number of viable of microbial cells in $\log_{10}(\text{CFU/ml})$ for samples in the form of coatings on the silicone tube (i.e. samples PVP^{tube}, (MgB₂-PVP)^{tube}_{0.25}, (MgB₂-PVP)^{tube}₃) tested with microbes in planktonic and biofilm states.

MgB₂-PVP composite coatings” and to provide some guiding lines in designing MgB₂-PVP coatings for future different applications, we present some useful details in the following paragraphs.

The thickness of the coatings was estimated from optical measurements at $\sim 200 \mu\text{m}$. The volume of the coatings for the foil and tube samples was 0.02 and 0.028 ml, respectively. When using 0.25 g and 3 g of MgB₂ to fabricate the samples, this results into a concentration of 0.6 and 7.2 mg/ml of the powder in the volume of PVP dissolved in ethanol (density of PVP was taken as 1.2 g/cm³ and density of MgB₂ as 2.6 g/cm³). Rescaling for the volume of the coating on the foil, the (MgB₂-PVP)^{foil}_{0.25} and (MgB₂-PVP)^{foil}₃ samples contain 9.75 and 38.2 mg of MgB₂, respectively. A similar calculation for the (MgB₂-PVP)^{tube}_{0.25} and (MgB₂-PVP)^{tube}₃ samples gives the values 13.65 and 53.5 mg, respectively.

To obtain a correct interpretation of our data, we should also take into consideration the PVP behavior in water. To this purpose, a bulk rectangular piece of PVP (0.5 cm \times 0.5 cm \times 0.1 cm) was prepared by casting a viscous solution of PVP in ethanol and subsequent drying in the air. The PVP sample with a volume 0.025 ml was introduced in water (50 ml). It dissolved in 3 h at room temperature, without stirring. The dissolution rate of PVP in water is 0.0083 ml/h.

In the in vitro antimicrobial tests addressed in “Antibacterial activity of MgB₂-PVP composite coatings”, samples were fully immersed in 750 μl of culture medium. The incubation time of 6, 24, and 48 h is higher than the dissolution time of PVP in water of 3 h. One also observes that the volume of the bulk PVP sample (0.025 ml) is comparable to that of the coatings (0.02 and 0.028 ml on the foil and on the tube, respectively). This suggests that the entire amount of MgB₂ powder in the coating was available to interact with the bacterial cells from the broth. Hence, the concentration of MgB₂ in the cell broth was as follows: 13, 50.9, 18.2, and 71.3 mg/ml for samples (MgB₂-PVP)^{foil}_{0.25}, (MgB₂-PVP)^{foil}₃, (MgB₂-PVP)^{tube}_{0.25}, and (MgB₂-PVP)^{tube}₃, respectively. These values are comparable, or they are one order of magnitude higher than the MIC and MBC values mentioned in “Cytocompatibility of MgB₂ powders”. They are also about three orders of magnitude larger than the toxicity limit of the powders. Interaction of MgB₂ with water, culture media, or body fluids is complex and needs further investigations. Some information for Mg, MgO, Mg(OH)₂ and MgB₂ was reported in Refs.^{26,27,36,39–41}. The involved processes develop in multistep sequences specific for each phase. Moreover, the reaction products, kinetic factors, and environmental conditions will ensure, or not, the background for antibacterial activity evolution with time. For example, the reaction of MgB₂ with water leads to formation of Mg(OH)₂, while boron in water forms boric acid. Due to low solubility in water, Mg(OH)₂ can passivate the surface of MgB₂ decreasing its efficiency. However

in physiologically relevant solutions $\text{Mg}(\text{OH})_2$ was found to dissociate³². On the other hand, in the reaction between MgB_2 and water, the H_2 -gas is released, and it can disrupt the passivating layer and can clean the surface of the MgB_2 particle. The overlapping of the processes, some of them with possibly opposite contributions, can explain the non-linear dependence of the bioactivity with time observed in our experiments from “Antibacterial activity of MgB_2 -PVP composite coatings”, but one should also consider the decreasing amount of MgB_2 , which is consumed in the interaction with cells and environment. Therefore, the current discussion and provided numbers draw attention on the necessity to properly design the coatings considering each specific application.

The mechanisms by which our composite coatings develop the antimicrobial effect deserves further targeted studies. In general, for nanomaterials the mechanisms^{11,42} are related to their influence on production of reactive oxygen species (ROS) (and in some cases of reactive nitrogen species RNA) through a catalytic action described by Haber/Weiss- and Fenton- type reactions^{13,43}, on electrostatic interaction that can impact the disruption/damage of the membrane integrity and potential so that metabolic functions of the cells are affected, and on the changes in the local environmental conditions e.g. through modification of aeration and pH. Depending on materials, cells, and environment there are specific features. For our composite coatings, PVP dissolves in water, MgB_2 is released and it becomes active interacting with the aqueous environment⁴⁴ and the cells (Fig. 2IV). PVP is inert in respect to its antimicrobial activity⁴⁵. The possibility of exfoliation of MgB_2 with formation of nano sheet materials such as hydroxyl functionalized Mg-deficient MgB_2 ³⁶ or borophane (HB)³⁷ may provide extra positive specific value in fighting the microbes: the 2D borophene-type materials are shown to have catalytic properties⁴⁶ that can impact directly or indirectly also bioprocesses. Furthermore, another 2D material, namely the graphene oxide emerged as an effective antimicrobial material⁴⁷ and, through similarities and extrapolation, one may expect that also the 2D nano boron-type materials derived from MgB_2 will play an important role as antimicrobial materials. However, at present, there are no experiments performed in this direction. In summary, different ionic species are generated because of the MgB_2 presence and they are at the origin of the developing reactions necessary for the antimicrobial effect (Fig. 2V).

The antimicrobial activity of MgB_2 assessed in our work revealed good efficiency against selected bacteria, e.g. for planktonic growth (Fig. 5) one may observe a decrease for $(\text{MgB}_2\text{-PVP})^{\text{foil}}$ of 7log/24 h against *E. coli*, 8log/24 h against *P. aeruginosa*, 8log/24 h against *S. aureus*, and 5log/24 h against *E. faecium*. Literature present other effective composite antibacterial materials, such as AgBr/nPVP⁴⁵ with a 5log/2 h against *E. coli*, and a lower concentration of the active substance (however, no cytotoxicity data are available for comparison). In Ref.⁴⁸ was reported a decrease of CFU/ml for nitric oxide (NO) of 8 log/24 h against *E. coli*/*A. baumannii*/*S. aureus*. In Ref.⁴⁹ for copper (Cu) the decrease of CFU/ml was of 4log/24 h against *E. coli*/*S. aureus*. In Ref.⁵⁰ was shown for silver (Ag) a decrease of CFU/ml of 5log/1.5 h against *E. coli*/*S. aureus*. It is important to note that a direct comparison between reported data is not entirely possible, as the assessment procedures are slightly different, the control samples do not start from the same level of cells population, and samples are different in shape and size and they target different applications.

Conclusion

In vitro MTS and LDH cytotoxicity tests of the MgB_2 activity on the HS27 dermal cell line indicated a toxicity limit in the range of 8.3–33.2 $\mu\text{g/ml}$ depending on the powder type. Three powders were tested and the most active was LTS. According to literature²³ this powder shows the highest amount of MgB_2 phase, impurity-free particle surfaces, the largest fraction of the particle size in the nano-range and the highest rate of pH increase. The LTS powder was further used for fabrication of MgB_2 -PVP coatings on plastic elements from a commercial urinary catheter. The as-prepared self-replenishing and biodegradable MgB_2 -PVP composite coatings with two compositions were tested at 6, 24, and 48 h of incubation time against the bacterial growth of *Staphylococcus aureus* ATCC 25923, *Enterococcus faecium* DMS 13590, *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853. Strains were in the planktonic and biofilm growth states. The coatings were efficient both against planktonic microbes and microbial biofilms when applied on plain, flexible plastic foils. Results are promising and recommend MgB_2 for designing efficient anti-infective solutions for various biomedical devices and systems.

Received: 20 October 2020; Accepted: 7 April 2021

Published online: 05 May 2021

References

1. Beceiro, A., Tomás, M. & Bou, G. Antimicrobial resistance and virulence: A successful or deleterious association in the bacterial world?. *Clin. Microbiol. Rev.* **26**, 185–230. <https://doi.org/10.1128/cmr.00059-12> (2013).
2. Lebeaux, D., Ghigo, J.-M. & Beloin, C. Biofilm-related infections: Bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. *Microbiol. Mol. Biol. Rev.* **78**, 510–543. <https://doi.org/10.1128/MMBR.00013-14> (2014).
3. Kalia, V. C. Quorum sensing inhibitors: An overview. *Biotechnol. Adv.* **31**, 224–245. <https://doi.org/10.1016/j.biotechadv.2012.10.004> (2013).
4. Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A. & Kutlu, O. Therapeutic nanoparticles and their targeted delivery applications. *Molecules* **25**, 2193. <https://doi.org/10.3390/molecules25092193> (2020).
5. Acar, J. F. Antibiotic synergy and antagonism. *Med. Clin. North Am.* **84**, 1391–1406. [https://doi.org/10.1016/S0025-7125\(05\)70294-7](https://doi.org/10.1016/S0025-7125(05)70294-7) (2000).
6. Bollenbach, T. Antimicrobial interactions: Mechanisms and implications for drug discovery and resistance evolution. *Curr. Opin. Microbiol.* **27**, 1–9. <https://doi.org/10.1016/j.mib.2015.05.008> (2015).
7. Doern, C. D. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. *J. Clin. Microbiol.* **52**, 4124–4128. <https://doi.org/10.1128/JCM.01121-14> (2014).
8. Patra, J. K. et al. Nano based drug delivery systems: Recent developments and future prospects. *J. Nanobiotechnol.* **16**, 71. <https://doi.org/10.1186/s12951-018-0392-8> (2018).
9. Karimi, M. et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. *Chem. Soc. Rev.* **45**, 1457–1501. <https://doi.org/10.1039/c5cs00798d> (2016).

10. Mohammadi, M. R. *et al.* Nanomaterials engineering for drug delivery: A hybridization approach. *J. Mater. Chem. B* **5**, 3995–4018. <https://doi.org/10.1039/c6tb03247h> (2017).
11. Beyth, N., Hourri-Haddad, Y., Domb, A., Khan, W. & Hazan, R. Alternative antimicrobial approach: Nano-antimicrobial materials. *Evid. Based Complement. Altern. Med.* **2015**(246012), 1–16. <https://doi.org/10.1155/2015/246012> (2015).
12. Popescu, R. C., Andronescu, E. & Vasile, B. S. Recent advances in magnetite nanoparticle functionalization for nanomedicine. *Nanomaterials* **9**, 1791. <https://doi.org/10.3390/nano9121791> (2019).
13. Collin, F. Chemical basis of reactive oxygen species reactivity and involvement in neurodegenerative diseases. *Int. J. Mol. Sci.* **20**, 2407. <https://doi.org/10.3390/ijms20102407> (2019).
14. Grumezescu, A. M. *Nanobiomaterials in Antimicrobial Therapy, Applications of Nanobiomaterials*, Vol. 6 (Elsevier, 2016). ISBN: 978-0-323-42864-4.
15. Vasilev, K., Cavallaro, A. & Zilm, P. Special issue: Antibacterial materials and coatings. *Molecules* **23**, 585. <https://doi.org/10.3390/molecules23030585> (2018).
16. Niemeyer, C. M. & Mirkin, C. A. *Nanobiotechnology, Concepts, Applications and Perspectives* (WILEY-VCH Verlag GmbH & Co. KGaA, 2004). ISBN: 3-527-30658-7.
17. Pelgrift, R. Y. & Friedman, A. J. Nanotechnology as a therapeutic tool to combat microbial resistance. *Adv. Drug Deliv. Rev.* **65**, 1803–1815. <https://doi.org/10.1016/j.addr.2013.07.011> (2013).
18. Blecher, K., Nasir, A. & Friedman, A. The growing role of nanotechnology in combating infectious disease. *Virulence* **2**, 395–401. <https://doi.org/10.4161/viru.2.5.17035> (2011).
19. Bühler, V. *Polyvinylpyrrolidone Excipients for Pharmaceuticals: Povidone, Crospovidone and Copovidone* 1–254 (Springer, 2005). <https://doi.org/10.1007/b138598>.
20. Haaf, F., Sanner, A. & Straub, F. Polymers of N-vinylpyrrolidone: Synthesis, characterization and uses. *Polym. J.* **17**, 143–152. <https://doi.org/10.1295/polymj.17.143> (1985).
21. Franco, P. & De Marco, I. The use of Poly(N-vinyl pyrrolidone) in the delivery of drugs: A review. *Polymers (Basel)* **12**, 1114. <https://doi.org/10.3390/polym12051114> (2020).
22. Batalu, D., Stanciu, A. M., Moldovan, L., Aldica, G. & Badica, P. Evaluation of pristine and Eu₂O₃-added MgB₂ ceramics for medical applications: Hardness, corrosion resistance, cytotoxicity and antibacterial activity. *Mater. Sci. Eng. C* **42**, 350–361. <https://doi.org/10.1016/j.msec.2014.05.046> (2014).
23. Badica, P. *et al.* MgB₂ powders and bioevaluation of their interaction with planktonic microbes, biofilms, and tumor cells. *J. Mater. Res. Technol.* <https://doi.org/10.1016/j.jmrt.2021.04.003> (2021).
24. Feneley, R. C. L., Hopley, I. B. & Wells, P. N. T. Urinary catheters: History, current status, adverse events and research agenda. *J. Med. Eng. Technol.* **39**, 459–470. <https://doi.org/10.3109/03091902.2015.1085600> (2015).
25. Lawrence, E. L. & Turner, I. G. Materials for urinary catheters: A review of their history and development in the UK. *Med. Eng. Phys.* **27**, 443–453. <https://doi.org/10.1016/j.medengphy.2004.12.013> (2005).
26. Aswal, D. K. *et al.* Degradation behavior of MgB₂ superconductor. *Phys. C* **363**, 208–214. [https://doi.org/10.1016/S0921-4534\(01\)00974-1](https://doi.org/10.1016/S0921-4534(01)00974-1) (2001).
27. Chen, Y. K., An, Z. & Chen, M. Competition mechanism study of Mg+H₂O and MgO+H₂O reaction. *Conf. Ser. Mater. Sci. Eng.* **394**, 022015. <https://doi.org/10.1088/1757-899X/394/2/022015> (2018).
28. Uluisik, I., Karakaya, H. C. & Koc, A. The importance of boron in biological systems. *J. Trace Elem. Med. Biol.* **45**, 156–162. <https://doi.org/10.1016/j.jtemb.2017.10.008> (2018).
29. Malich, G., Markovic, B. & Winder, C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. *Toxicology* **124**, 179–192. [https://doi.org/10.1016/S0300-483X\(97\)00151-0](https://doi.org/10.1016/S0300-483X(97)00151-0) (1997).
30. Barltrop, J., Owen, T., Cory, A. H. & Cory, J. G. 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans as cell-viability indicators. *Bioorg. Med. Chem. Lett.* **1**, 611–614. [https://doi.org/10.1016/S0960-894X\(01\)81162-8](https://doi.org/10.1016/S0960-894X(01)81162-8) (1991).
31. Riss, T. L. *et al.* Cell viability assays. in *Assay Guidance Manual* (2013) (eds Markossian, S. *et al.*). <http://www.ncbi.nlm.nih.gov/books/NBK144065>.
32. Fotakis, G. & Timbrell, J. A. In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. *Toxicol. Lett.* **160**, 171–177. <https://doi.org/10.1016/j.toxlet.2005.07.001> (2006).
33. Allen, M., Millett, P., Dawes, E. & Rushton, N. Lactate dehydrogenase activity as a rapid and sensitive test for the quantification of cell numbers in vitro. *Clin. Mater.* **16**, 189–194. [https://doi.org/10.1016/0267-6605\(94\)90116-3](https://doi.org/10.1016/0267-6605(94)90116-3) (1994).
34. Kaja, S., Payne, A. J., Naumchuk, Y. & Koulen, P. Quantification of lactate dehydrogenase for cell viability testing using cell lines and primary cultured astrocytes. *Curr. Protoc. Toxicol.* **72**, 1–10. <https://doi.org/10.1002/cptx.21> (2017).
35. Lim, J. Y. *et al.* Effects of surface-treated boron powder using chemical solvents on MgB₂ bulk superconductors. *Prog. Supercond. Cryogenics* **20**, 11–14. <https://doi.org/10.9714/psac.2018.20.3.011> (2018).
36. Das, S. K., Bedar, A., Kannan, A. & Jasuja, K. Aqueous dispersions of few-layer-thick chemically modified magnesium diboride nanosheets by ultrasonication assisted exfoliation. *Sci. Rep.* **5**, 10522. <https://doi.org/10.1038/srep10522> (2015).
37. Nishino, H. *et al.* Formation and characterization of hydrogen boride sheets derived from MgB₂ by cation exchange. *Am. Chem. Soc.* **139**, 13761–13769. <https://doi.org/10.1021/jacs.7b06153> (2017).
38. George, I. *et al.* In vitro evaluation of MgB₂ powders as novel tools to fight fungal biodeterioration of heritage buildings and objects. *Front. Mater.* **7**, 601059. <https://doi.org/10.3389/fmats.2020.601059> (2021).
39. Lide, D. R. *Handbook of Chemistry and Physics* 73rd edn (Taylor & Francis, 1992). ISBN 0849304733, 9780849304736.
40. Wetteland, C. L. *et al.* Dissociation of magnesium oxide and magnesium hydroxide nanoparticles in physiologically relevant fluids. *J. Nanopart. Res.* **20**, 215. <https://doi.org/10.1007/s11051-018-4314-3> (2018).
41. Poinern, G. E. J., Brundavanam, S. & Fawcett, D. Biomedical magnesium alloys: A review of material properties, surface modifications and potential as a biodegradable orthopaedic implant. *Am. J. Biomed. Eng.* **2**, 218–240. <https://doi.org/10.5923/j.ajbe.20120.206.02> (2012).
42. Khatoun, Z., McTiernan, C. D., Suuronen, E. J., Mah, T.-F. & Alarcon, E. I. Bacterial biofilm formation on implantable devices and approaches to its treatment and prevention. *Heliyon* **4**, e01067. <https://doi.org/10.1016/j.heliyon.2018.e01067> (2018).
43. Madkour, L. H. Function of reactive oxygen species (ROS) inside the living organisms and sources of oxidants. *Pharm. Sci. Anal. Res. J.* **2**, 180023 (2019). <https://chembiopublishers.com/PSARJ/PSARJ1800023.pdf>.
44. Sadeghi, E., Peighambari, N. S., Khatamian, M., Unal, U. & Aydemir, U. Metal doped layered MgB₂ nanoparticles as novel electrocatalysts for water splitting. *Sci. Rep.* **11**, 3337. <https://doi.org/10.1038/s41598-021-83066-7> (2021).
45. Sambhy, V., MacBride, M. M., Peterson, B. R. & Sen, A. Silver bromide nanoparticle/polymer composites: Dual action tunable antimicrobial materials. *J. Am. Chem. Soc.* **128**, 9798–9808. <https://doi.org/10.1021/ja061442z> (2006).
46. Fujino, A. *et al.* Hydrogenated borophene shows catalytic activity as solid acid. *ACS Omega* **4**, 14100–14104. <https://doi.org/10.1021/acsomega.9b02020> (2019).
47. Li, P. *et al.* Synthesis, characterization, and bactericidal evaluation of chitosan/guanidine functionalized graphene oxide composites. *Molecules* **22**, 12. <https://doi.org/10.3390/molecules22010012> (2017).
48. Pegalajar-Jurado, A. *et al.* Nitric oxide-releasing polysaccharide derivative exhibits 8-log reduction against *Escherichia coli*, *Acinetobacter baumannii* and *Staphylococcus aureus*. *J. Control. Release* **220**, 617. <https://doi.org/10.1016/j.jconrel.2015.09.015> (2015).

49. Esteban-Cubillo, A., Pecharromán, C., Aguilar, E., Santarén, J. & Moya, J. S. Antibacterial activity of copper monodispersed nanoparticles into sepiolite. *J. Mater. Sci.* **41**, 5208. <https://doi.org/10.1007/s10853-006-0432-x> (2006).
50. Jung, W. K. *et al.* Antibacterial activity and mechanism of action of the silver ion in *Staphylococcus aureus* and *Escherichiacoli*. *Appl. Environ. Microbiol.* **74**, 2171. <https://doi.org/10.1128/AEM.02001-07> (2008).

Acknowledgements

Authors acknowledge Romanian National Authority for Scientific Research and Innovation (UEFISCDI), Italian Ministry of Education, University and Research (MIUR) and EU for financial support, project 74-COFUND-M-ERA.NET II—BIOMB. Support from UEFISCDI through the project 5PTE/2020—BIOTEHKER is also acknowledged. The funding had no role in study, design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Author contributions

Conceptualization: P.B., N.D.B., M.C.C.; methodology P.B., M.C.C.; validation P.B., M.C.C.; analysis: P.B., N.D.B., M.C.C., M.B., M.A.G., G.A., M.E., G.G.P., M.P., L.G.M., B.G.D., L.O., A.B., B.P., L.O., V.B., A.A., M.T.; investigation; writing—original draft preparation: P.B.; writing—review and editing P.B., N.D.B., M.C.C., G.A., M.T.; visualization: P.B.; supervision P.B.; project administration P.B., N.D.B., M.C.C., M.T.; funding acquisition: M.T., P.B.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to P.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021